Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial-Reference-Cited by-同舟云学术

Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial

Published:2024-02 Issue:2 Volume:23 Page:157-167
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Mazighi Mikaël,Köhrmann Martin,Lemmens Robin,Lyrer Philippe A,Molina Carlos A,Richard Sébastien,Toni Danilo,Plétan Yannick,Sari Anouar,Meilhoc Adeline,Jandrot-Perrus Martine,Binay Sophie,Avenard Gilles,Comenducci Andrea,Grouin Jean-Marie,Grotta James C,Albucher Jean François,Alonso Angelika,Berrouschot Jörg,Cordonnier Charlotte,de Raedt Sylvie,Desfontaines Philippe,Doche Emilie,Hemelsoet Dimitri,Macian-Montoro Francisco,Masjuan Jaime,Obadia Michael,Peeters André,Pelz Johann,Reiner Peggy,Segura Tomas,Serena Joaquin,Sibon Igor,Tembl Jose I.,Vannier Stéphane,Zuber Mathieu

Publisher

Elsevier BV

Reference42 articles.

1. Management of Acute Ischemic Stroke;Herpich;Crit Care Med,2020

2. Do Clinicians Overestimate the Severity of Intracerebral Hemorrhage?

3. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke;Berge;Eur Stroke J,2021

4. Thrombolysis in acute ischaemic stroke: an update;Robinson;Ther Adv Chronic Dis,2011

5. Development and testing of thrombolytics in stroke;Nikitin;J Stroke,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mendelian Randomization and Bayesian Colocalization Analysis Implicate Glycoprotein VI as a Potential Drug Target for Cardioembolic Stroke in South Asian Populations;Journal of the American Heart Association;2024-08-20

2. The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in mice;European Heart Journal;2024-08-16

3. Un anticorps monoclonal ciblant la glycoprotéine VI plaquettaire : une nouvelle génération d’antithrombotique sans risque hémorragique à la phase aiguë de l’infarctus cérébral;Bulletin de l'Académie Nationale de Médecine;2024-08

4. De l’identification d’un récepteur plaquettaire (GPVI) au développement d’un candidat antiplaquettaire découplé du risque hémorragique;Bulletin de l'Académie Nationale de Médecine;2024-08

5. Modifying platelets at their birth: anti-thrombotic therapy without haemorrhage;Frontiers in Pharmacology;2024-03-18